These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37771288)

  • 21. Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly.
    Hoshi SL; Shono A; Seposo X; Okubo R; Kondo M
    Vaccine; 2022 Nov; 40(49):7057-7064. PubMed ID: 36273987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease.
    Huang L; McDade CL; Perdrizet JE; Wilson MR; Warren SA; Nzenze S; Sewdas R
    Infect Dis Ther; 2023 Mar; 12(3):933-950. PubMed ID: 36774428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of pediatric immunization program with 15-valent pneumococcal conjugate vaccine in Japan.
    Tajima A; Abe M; Weaver J; Huang M
    J Med Econ; 2023; 26(1):1034-1046. PubMed ID: 37555281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands.
    Wilson M; McDade C; Beby-Heijtel AT; Waterval-Overbeek A; Sundaram V; Perdrizet J
    Infect Dis Ther; 2023 Jul; 12(7):1809-1821. PubMed ID: 37318710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom.
    Wilson M; Lucas A; Mendes D; Vyse A; Mikudina B; Czudek C; Ellsbury GF; Perdrizet J
    Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outpatient Visits and Antibiotic Use Due to Higher-Valency Pneumococcal Vaccine Serotypes.
    King LM; Andrejko KL; Kabbani S; Tartof SY; Hicks LA; Cohen AL; Kobayashi M; Lewnard JA
    J Infect Dis; 2024 Oct; 230(4):821-831. PubMed ID: 38498565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
    Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
    Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults.
    Marbaix S; Mignon A; Taelman A; Averin A; Atwood M; Vietri J
    Expert Rev Vaccines; 2023; 22(1):1008-1021. PubMed ID: 37872765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea.
    Kim HY; Park SB; Kang ES; Lee SM; Kim HJ; Wasserman M
    Hum Vaccin Immunother; 2021 Mar; 17(3):909-918. PubMed ID: 32783576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain.
    Cantarero D; Ocaña D; Onieva-García MÁ; Rodríguez-García J; Gálvez P; Méndez C; Crespo C; López-Ibáñez de Aldecoa A
    Vaccine; 2023 Aug; 41(36):5342-5349. PubMed ID: 37479615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age.
    Wasserman MD; Perdrizet J; Grant L; Hayford K; Singh S; Saharia P; Horn EK; Farkouh RA
    Infect Dis Ther; 2021 Dec; 10(4):2701-2720. PubMed ID: 34633639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.
    Owusu-Edusei K; Favre-Bulle A; Tsoumani E; Mutschler T; Cossrow N
    Vaccine; 2024 May; 42(13):3239-3246. PubMed ID: 38609806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England.
    Danelian G; Burton L; Bayley T; Sanchez-Marroquin A; Park J; Manley H; Choi Y; Andrews N; Ladhani S; Earnshaw A; Gritzfeld JF; Trotter C; Panovska-Griffiths J
    Vaccine; 2024 Jul; 42(18):3838-3850. PubMed ID: 38763851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States.
    Prasad N; Stoecker C; Xing W; Cho BH; Leidner AJ; Kobayashi M
    Vaccine; 2023 May; 41(18):2914-2921. PubMed ID: 37012118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mathematical modeling of pneumococcal transmission dynamics in response to PCV13 infant vaccination in Germany predicts increasing IPD burden due to serotypes included in next-generation PCVs.
    Horn M; Theilacker C; Sprenger R; von Eiff C; Mahar E; Schiffner-Rohe J; Pletz MW; van der Linden M; Scholz M
    PLoS One; 2023; 18(2):e0281261. PubMed ID: 36791091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
    Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
    BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Healthcare Costs for Pneumococcal Disease in the Era of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine: A Population-Based Study.
    Vadlamudi NK; Sadatsafavi M; Patrick DM; Rose C; Hoang L; Marra F
    Value Health; 2022 Sep; 25(9):1510-1519. PubMed ID: 35466049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value.
    Janssens E; Flamaing J; Vandermeulen C; Peetermans WE; Desmet S; De Munter P
    Acta Clin Belg; 2023 Feb; 78(1):78-86. PubMed ID: 35171752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Effectiveness Analysis of Routine Childhood Immunization with 20-Valent versus 15-Valent Pneumococcal Conjugate Vaccines in Germany.
    Huang M; Weaver JP; Elbasha E; Weiss T; Banniettis N; Feemster K; White M; Kelly MS
    Vaccines (Basel); 2024 Sep; 12(9):. PubMed ID: 39340075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants.
    Perdrizet J; Santana CFS; Senna T; Alexandre RF; Sini de Almeida R; Spinardi J; Wasserman M
    Hum Vaccin Immunother; 2021 Apr; 17(4):1162-1172. PubMed ID: 32966176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.